Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04552808 | To Evaluate the Pharmacokinetics and Safety of Yimitasvir Phosphate Capsules in Subjects With Moderate and Severe Liver Function Impairment and in Healthy Subjects | PHASE1 | COMPLETED | 16 | — | — | Oct 19, 2020 | Jun 9, 2022 | Oct 27, 2022 | 1 | China |
Incidence of adverse events
Maximum plasma concentration of study drugs
Maximum plasma concentration of study drugs
| Arm | Type | Description |
|---|---|---|
| Yimitasvir Phosphate Capsules | EXPERIMENTAL | The mechanism of action of Yimitasvir is the specific inhibition of HCV non-structural protein NS5A |
| Name | Type | Description |
|---|---|---|
| Yimitasvir Phosphate | DRUG | Cohort A: On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects |
Inclusion Criteria: 1. Sign the informed consent form before the trial and fully understand the contents of the trial, the process and possible adverse reactions. 2. subjects and must be 18 to 70 years of age inclusive. 3. Subjects (including partners) have no pregnancy plan within 3 months after t...